BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

BioPharma Clinical Trials

Ascletis approved for Phase IIa clinical trial of ASC10 for RSV infection in China

--Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far --Do...

May 09, 2023 | News

Bliss Biopharmaceutical Collaborates with Eisai for Clinical Trial of BB-1701 with Strategic Option

This collaboration with Eisai is an important advancement in BlissBio's corporate development plan to further develop BB-1701 globally and help advance BB-...

May 08, 2023 | News

EirGenix's Breast Cancer Biosimilar EG1206A Meets Phase 1 Trial Goals

Comparing EG1206A to Roche's Perjeta® US and EU, results of the clinical data analysis show that the main test indicators have met the pharmacokinetics...

May 08, 2023 | News

Cambridge Infinitus Research Centre Launches AI-based ERnet Platform for Cellular Health Studies.

With an impact factor of 47.99, Nature Methods is the world's leading international publication for biochemical research methodology. Upon public...

May 05, 2023 | News

ABM Initiates Phase I Clinical Trial of MEK Inhibitor for Solid Tumor, Doses First Patient

MEK (mitogen-activated protein kinase kinase), a key kinase of the MAPK pathway, is frequently activated in various cancers, including those with RAS mutat...

May 05, 2023 | News

Nouscom Reaches Clinical Phase II Using ProBioGen’s AGE1.CR.pIX® Production Platform

Nous-209 has been developed using the Nouscom's viral vector platform, which includes adenoviral and Modified Vaccinia Ankara (MVA) vectors, with MVA vecto...

May 04, 2023 | News

Revolutionizing Drug Development: IQVIA's David Cameron on the Power of Innovative Trial Designs

Can you tell us about your role as Senior Director & Global Head of Novel Trial Design at IQVIA? The Novel Trial Design initiative at IQ...

May 09, 2023 | News

The Impact of Digital Health Technologies in Oncology: Current State and Future Directions

Digital health has revolutionized the way healthcare is delivered and managed in recent years. Oncology is one field that has benefited significantly from ...

May 03, 2023 | Opinion

Cellenkos Doses First Patient with CK0803 Cell Therapy for ALS Treatment

Cellenkos® Inc., a clinical stage biotechnology company focused on developing allogeneic, off-the-shelf, T regulatory cell therapies for treatment...

May 03, 2023 | News

New Data Confirms Efficacy of ZIRCON Study in Imaging Kidney Cancer Masses Smaller Than 2cm at AUA

The results were featured in a late-breaking oral presentation delivered on Sunday, 30 April 2023 (CST) by Associate Professor Brian Shuch, ...

May 01, 2023 | News

ALX Oncology collaborates with Sanofi to evaluate Evorpacept with SARCLISA for multiple myeloma

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 ...

April 28, 2023 | News

RNAimmune's RV-1730 COVID-19 booster vaccine receives FDA clearance for Phase 1 trial.

The proposed clinical study will involve in an evaluation of RV-1730 for its safety and prophylaxis efficacy against SARS-CoV-2 infection with people...

April 28, 2023 | News

I-Mab Doses First Patient in Phase 3 Study of Lemzoparlimab for MDS in China

The Phase 3 trial is a randomized, controlled, open-label, multi-center study to evaluate the efficacy and safety of lemzoparlimab in combination with AZA ...

April 25, 2023 | News

Everest Medicines Launches First-in-Disease Therapy for IgA Nephropathy in China's Hainan Boao Pilot Zone.

The launch of this early-access program in Hainan marks the beginning of a new treatment era for IgA nephropathy in China, where Everest can...

April 24, 2023 | News

Stay Connected